SAGE Therapeutics (SAGE) Misses Q1 EPS by 12c

SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($3.37), $0.12 worse than the analyst estimate of ($3.25).

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery